Hippocampal atrophy as a surrogate of neuronal involvement in Fabry disease

Journal of Inherited Metabolic Disease

Volumn 35, Issue 2, 2012, Pages 363-367

  Fellgiebel, Andreas ^a   Wolf, Dominik O ^a   Kolodny, Edwin ^b   Müller, Matthias J ^a  

^a UNIVERSITY MEDICAL CENTER MAINZ   (Germany)

^b NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; ARTICLE; BRAIN ATROPHY; BRAIN SIZE; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE SEVERITY; FABRY DISEASE; FEMALE; GRAY MATTER VOLUME; HIPPOCAMPAL ATROPHY; HIPPOCAMPAL VOLUME; HUMAN; LEARNING; MALE; MEMORY DISORDER; NERVOUS SYSTEM PARAMETERS; NEUROPSYCHOLOGICAL TEST; NUCLEAR MAGNETIC RESONANCE IMAGING; VERBAL MEMORY; VOLUMETRY; WHITE MATTER LESION; WHITE MATTER VOLUME;

ADULT; ATROPHY; BRAIN; COGNITION DISORDERS; COHORT STUDIES; DEPRESSION; FABRY DISEASE; FEMALE; HIPPOCAMPUS; HUMANS; LONGITUDINAL STUDIES; MALE; MEMORY DISORDERS; NEURONS;

EID: 84863455374     PISSN: 01418955     EISSN: 15732665     Source Type: Journal    
DOI: 10.1007/s10545-011-9390-9     Document Type: Article

References (19)

1. Albrecht J, Dellani PR, Müller MJ et al (2007) Voxel based analyses of diffusion tensor imaging in Fabry disease. J Neurol Neurosurg Psychiatry 78:964-969
2. Ashburner J, Friston KJ (2000) Voxel-based morphometry-the methods. NeuroImage 11:805-821
3. Crutchfield KE, Patronas NJ, Dambrosia JM et al (1998) Quantitative analysis of cerebral vasculopathy in patients with Fabry disease. Neurology 50:1746-1749
4. Desnick RJ, Brady R, Barranger J et al (2003) Fabry disease, an under-recognized multisystemic disorder: expert recommenda- tions for diagnosis, management, and enzyme replacement therapy. Ann Intern Med 138:338-346
5. deVeber GA, Schwarting GA, Kolodny EH et al (1992) Fabry disease: immunocytochemical characterization of neuronal involvement. Ann Neurol 31:409-415
6. Fellgiebel A, Müller MJ, Mazanek M et al (2005) White matter lesion severity in male and female patients with Fabry disease. Neurology 65:600-602
7. Fellgiebel A, Muller MJ, Ginsberg L (2006) CNS manifestations of Fabry's disease. Lancet Neurol 5:791-795
8. Fellgiebel A, Keller I, Marin D et al (2009) Diagnostic utility of different MRI and MR angiography measures in Fabry disease. Neurology 72:63-68
9. Godin O, Maillard P, Crivello F et al (2009) Association of white- matter lesions with brain atrophy markers: the three-city Dijon MRI study. Cerebrovasc Dis 28:177-184
10. Hamilton M (1986) The Hamilton Rating Scale for Depression. In: Sartorius N, Ban TA (eds) Assessment of depression. Springer Verlag, Berlin, pp 143-152
11. Kaye EM, Kolodny EH, Logigian EL et al (1988) Nervous system involvement in Fabry's disease: clinicopathological and biochemical correlation. Ann Neurol 23:505-509
12. Mitsias P, Levine SR (1996) Cerebrovascular complications ofFabry's disease. Ann Neurol 40:8-17
13. Moore DF, Ye F, Schiffmann R et al (2003) Increased signal intensity in the pulvinar on T1-weighted images: a pathognomonic MR imaging sign ofFabry disease. Am J Neuroradiol 24:1096-1101
14. Niemann K, Hammers A, Coenen VA et al (2000) Evidence of a smaller left hippocampus and left temporal horn in both patients with first episode schizophrenia and normal control subjects. Psychiatry Res 99:93-110
15. Nitkunan A, Lanfranconi S, Charlton RA et al (2010) Brain atrophy and cerebral small vessel disease: a prospective follow-up study. Stroke 42:133-138
16. Okeda R, Nisihara M (2008) An autopsy case of Fabry disease with neuropathological investigation of the pathogenesis of associated dementia. Neuropathology 28:532-540
17. Schermuly I, Müller MJ, Müller KM et al (2010) Neuropsychiatric symptoms and brain structural alterations in Fabry disease. Eur J Neurol 18:347-353
18. Takanashi J, Barkovich AJ, Dillon WP, Sherr EH, Hart KA, Packman S (2003) T1 hyperintensity in the pulvinar: key imaging feature for diagnosis ofFabry disease. AJNR Am J Neuroradiol24:916-921
19. Whybra C, Kampmann C, Krummenauer F et al (2004) The Mainz Severity Score Index: a new instrument for quantifying the Anderson-Fabry disease phenotype, and the response of patients to enzyme replacement therapy. Clin Genet 65:299-307